A pharmacokinetic study of pyridoxal-5*-phosphate and pyrixodine

A pharmacokinetic study of pyridoxal-5*-phosphate and pyrixodine - Vitamin B6 study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45563

Enrollment

Registered

2017-05-03

Start date

2017-06-29

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

onderzoek naar opname en omzetting van pyridoxal-5'-fosfaat (farmacokinetiek) Uptake and metabolism of different forms of vitamin B6

Interventions

This study is a pharmacokinetic study in which healthy adults will daily receive 50 mg pyridoxal-5'-phosphate (PLP) or 50 mg pyridoxine (PN) during 1 week.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy, adults, both male and female, aged between 20 and 50 years with normal liver and kidney function, with normal BMI (between 19 and 25), and able to come to the research laboratory on 3 specified occasions within a one week period

Exclusion criteria

Exclusion criteria: use of medication (with the exception of oral contraceptives), use of vitamin supplements during the past 6 months, detectable plasma level of pyridoxine, non-normal liver and kidney functions, BMI 25, alcohol consumption > 2 drinks/day,

Design outcomes

Primary

Measure	Time frame
Using LC-MS-QTOF plasma concentrations of pyridoxine (PN) will be measured	—

Secondary

Measure	Time frame
Plasma concentrations of other B6 vitamers and metabolites: pyridoxal (PL), pyridoxamine (PM), and the phosphorylated derivative pyridoxal 5*- phosphate (PLP) and 4-Pyridoxinic acid (PA).	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)